Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Helal

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|December 21, 2016
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide FunctionalityChristopher R Butler, Kevin Ogilvie, Luis Martinez-Alsina, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189Antonia F Stepan, Tuan P Tran, Christopher J Helal, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
Journal of Medicinal Chemistry|September 29, 2017
The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) ImagingLei Zhang, Laigao Chen, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Cell Chemical Biology|September 30, 2020
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoEUthpala Seneviratne, Zhen Huang, Christopher W Am Ende, et al.
Medchemcomm|August 16, 2018
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacyMartin Pettersson, Douglas S Johnson, Danica A Rankic, et al.
Journal of Medicinal Chemistry|February 20, 2015
Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug designChristopher R Butler, Michael A Brodney, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|March 3, 2018
Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of NeuroinflammationLaura A McAllister, Christopher R Butler, Scot Mente, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2012
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivoRobin J Kleiman, Douglas S Chapin, Curt Christoffersen, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|December 21, 2016
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide FunctionalityChristopher R Butler, Kevin Ogilvie, Luis Martinez-Alsina, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189Antonia F Stepan, Tuan P Tran, Christopher J Helal, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
Journal of Medicinal Chemistry|September 29, 2017
The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) ImagingLei Zhang, Laigao Chen, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Cell Chemical Biology|September 30, 2020
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoEUthpala Seneviratne, Zhen Huang, Christopher W Am Ende, et al.
Medchemcomm|August 16, 2018
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacyMartin Pettersson, Douglas S Johnson, Danica A Rankic, et al.
Journal of Medicinal Chemistry|February 20, 2015
Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug designChristopher R Butler, Michael A Brodney, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|March 3, 2018
Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of NeuroinflammationLaura A McAllister, Christopher R Butler, Scot Mente, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2012
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivoRobin J Kleiman, Douglas S Chapin, Curt Christoffersen, et al.
Pageof 4